TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An update from Outlook Therapeutics ( (OTLK) ) is now available.
On November 13, 2025, Outlook Therapeutics announced that the FDA acknowledged receipt of its resubmitted Biologics License Application for ONS-5010, a bevacizumab-vikg product. The FDA classified the application as a Class 1 review, setting a two-month review period and a PDUFA goal date of December 31, 2025, which could significantly impact the company’s market positioning and stakeholder interests.
The most recent analyst rating on (OTLK) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Outlook Therapeutics stock, see the OTLK Stock Forecast page.
Spark’s Take on OTLK Stock
According to Spark, TipRanks’ AI Analyst, OTLK is a Underperform.
Outlook Therapeutics is facing critical financial challenges with no revenue and high leverage, posing substantial risks. The technical analysis shows weak momentum with mixed signals, while the valuation indicates non-profitability. These factors collectively suggest a low stock score.
To see Spark’s full report on OTLK stock, click here.
More about Outlook Therapeutics
Outlook Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing and commercializing monoclonal antibody therapeutics for various ophthalmic indications.
Average Trading Volume: 3,768,584
Technical Sentiment Signal: Sell
Current Market Cap: $56.86M
Find detailed analytics on OTLK stock on TipRanks’ Stock Analysis page.